Clinically, the prognostic significance of deletion 17p, which involves the TP53 gene, has been extensively studied and has been well documented in the context of several malignancies, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). This evidence concerns the gene TP53 and non-small cell lung carcinoma.